Sunitinib

Generic Name: Sunitinib

Brand Names: Sutent, Sunitinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₇FN_₄O_₂

CAS Number: 557795-19-4

Unique Ingredient Identifier: V99T50803M

Background: Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...

Indication: Sunitinib is indicated for the following conditions:

Associated Conditions: Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin

Associated Therapies: -

Clinical Trials

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Phase 3

Active, not recruiting

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Ripretinib
Drug: Sunitinib

First Posted Date: 2018-09-17

Last Posted Date: 2024-01-02

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 453

Registration Number: NCT03673501

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇺🇸
UCLA Hematology Oncology Center - Main Site, Los Angeles, California, United States

and more 117 locations

Sunitinib in Sarcomas of the Central Nervous System

Phase 2

Terminated

Conditions: Central Nervous System Sarcoma
Gliosarcoma

Interventions: Drug: Sunitinib
Device: wGT3x-BT

First Posted Date: 2018-08-22

Last Posted Date: 2022-04-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT03641326

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

Phase 2

Conditions: Clear Cell Renal Cell Carcinoma

Interventions: Drug: Sunitinib

First Posted Date: 2018-07-19

Last Posted Date: 2019-09-04

Lead Sponsor: Instituto do Cancer do Estado de São Paulo

Target Recruit Count: 7

Registration Number: NCT03592199

Locations: 🇧🇷
Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil

Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors

Not Applicable

Recruiting

Conditions: Kidney Cancer

Interventions: Combination Product: CK2 and ATM inhibitors serine/ threonin Kinase combination
Drug: Temsirolimus
Drug: Sunitinib
Drug: Pazopanib

First Posted Date: 2018-06-27

Last Posted Date: 2020-01-18

Lead Sponsor: University Hospital, Grenoble

Target Recruit Count: 100

Registration Number: NCT03571438

Locations: 🇫🇷
Grenoble Alps Hospital, Grenoble, France

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Malignant Neoplasms of Urinary Tract
Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
Stage IV Renal Cell Cancer AJCC v8
Unclassified Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Sarcomatoid Renal Cell Carcinoma

Interventions: Drug: Cabozantinib
Drug: Sunitinib Malate

First Posted Date: 2018-05-31

Last Posted Date: 2024-06-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT03541902

Locations: 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson Regional Care Center-Katy, Houston, Texas, United States

Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Sunitinib

First Posted Date: 2018-05-09

Last Posted Date: 2019-09-18

Lead Sponsor: Spanish Oncology Genito-Urinary Group

Target Recruit Count: 62

Registration Number: NCT03519542

Locations: 🇪🇸
Hospital Universiario de León, León, Spain
🇪🇸
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
🇪🇸
Hospital Marqués de Valdecilla, Santander, Cantabria, Spain

and more 9 locations

Pembrolizumab and Sunitinib Malate in Treating Participants with Refractory Metastatic or Unresectable Thymic Cancer

Phase 2

Recruiting

Conditions: Thymic Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Sunitinib Malate

First Posted Date: 2018-03-13

Last Posted Date: 2024-11-04

Lead Sponsor: Dwight Owen

Target Recruit Count: 30

Registration Number: NCT03463460

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)

Phase 2

Conditions: Type B3 Thymoma
Thymic Carcinoma

Interventions: Drug: Sunitinib

First Posted Date: 2018-02-28

Last Posted Date: 2021-06-09

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 56

Registration Number: NCT03449173

Locations: 🇮🇹
National Cancer Institute, Milan, Italy

Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma

Phase 2

Withdrawn

Conditions: Renal Cell Carcinoma

Interventions: Drug: Propranolol
Drug: Sunitinib

First Posted Date: 2017-10-27

Last Posted Date: 2019-01-09

Lead Sponsor: Military Institute od Medicine National Research Institute

Registration Number: NCT03323710

Locations: 🇵🇱
Military Institute of Medicine, Warsaw, Mazowieckie, Poland

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Recruiting

Conditions: Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors

Interventions: Drug: Erlotinib
Drug: Dasatinib
Drug: Axitinib
Drug: Bosutinib
Drug: Crizotinib
Drug: Nivolumab plus Ipilimumab
Drug: Olaparib
Drug: Palbociclib
Drug: Sunitinib
Drug: Temsirolimus
Drug: Trastuzumab plus Pertuzumab
Drug: Vemurafenib plus Cobimetinib
Drug: Vismodegib
Drug: Tucatinib

First Posted Date: 2017-09-29

Last Posted Date: 2024-11-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 720

Registration Number: NCT03297606

Locations: 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy